An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 in Addition to Anti-PD-1 or Anti-PD-L1 Monoclonal Antibody Therapy in Patients With Solid Tumors is a PHASE1 clinical asset sponsored by NEC Bio B.V in Solid Tumor. SEO and diligence focus: NECVAX-NEO1, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.